|
gptkbp:instanceOf
|
gptkb:antiviral_drug
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AH02
|
|
gptkbp:bioavailability
|
80%
|
|
gptkbp:CASNumber
|
196618-13-0
|
|
gptkbp:chemicalFormula
|
C16H28N2O4
|
|
gptkbp:contraindication
|
hypersensitivity to oseltamivir
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
gptkb:neuraminidase_inhibitor
|
|
gptkbp:eliminationHalfLife
|
6-10 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstApprovedCountry
|
gptkb:Switzerland
|
|
gptkbp:form
|
capsule
oral suspension
powder for oral suspension
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:genericName
|
gptkb:oseltamivir
|
|
gptkbp:indication
|
prevention of influenza
treatment of influenza
|
|
gptkbp:legalStatus
|
expired
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
gptkb:neuraminidase_inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:notRecommendedFor
|
children under 1 year
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children over 1 year
|
|
gptkbp:prodrugOf
|
oseltamivir carboxylate
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
headache
neuropsychiatric effects
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:usedFor
|
gptkb:influenza_A
gptkb:influenza_B
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Roche
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Tamiflu
|